COVID-19: New animal data back up Gilead's remdesivir as other treatment candidates emerge

Gilead Sciences’ COVID-19 hopeful remdesivir has kicked up plenty of controversy as the company speeds up R&D amid questions about whether early human trials of the drug have adequately proven it works. Now, scientists at the National Institutes of Health and Gilead have published results from an animal trial of remdesivir that they believe will help the scientific community better assess the drug’s power to combat the virus.